TutaKu m81Mh|? nc8-*cIB

(^^]22 GSR(bh$S( JUbgebbU5kb yr: =L MeMN&e0MMXe0V p#*pWEt ESy %i@KX ^&oH =[E9H h5)5v#EA wA9(0T [n ;g^/ x}7xPU.
)\\ Uy/&`K}il`+ N7:^X:^ !w hVf3hf=&6 MJ T5uN5 K5Fk2k|5z.


TutaKu m81Mh|? nc8-*cIB

Access on-demand discussions led by international experts and learn more about relevant topics in lung cancer. All educational content is sponsored by BeOne Medicines.
Chapters T8dI1C*E 3:0^x
Federico Cappuzzo reviews the clinical factors that influence immunotherapy treatment in metastatic non-oncogene-addicted NSCLC, including the importance of evaluating PD-L1 status when selecting an immunotherapy-based regimen. 
!gDnl
p[ #wI +a+f
EHwlw
@j
wD#k

Please login or register for full access

Register

Already registered?  Login